ADMA250117C22000
- 0.15
- -0.05-25.00%
ADMA Biologics Newsroom
ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
4 Biotech Stocks Most Wall Street Analysts Are Bullish About
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $28
ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip?
Looking Into ADMA Biologics's Recent Short Interest
Can Adma Biologics (ADMA) Climb 25.5% to Reach the Level Wall Street Analysts Expect?
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating
10 Health Care Stocks With Whale Alerts In Today's Session
ADMA Biologics (NASDAQ:ADMA) Seems To Use Debt Quite Sensibly
Adma Biologics (ADMA) Is on the Move, Here's Why the Trend Could Be Sustainable
ADMA Biologics Announces Board Resignations and Appointments
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $24
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
NASDAQ New 52-Week Highs And Lows
Earnings Beat: Here's What ADMA Biologics, Inc. (NASDAQ:ADMA) Analysts Are Forecasting For Next Year
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $24
ADMA Biologics Is Maintained at Strong Buy by Raymond James
ADMA Biologics Analyst Ratings
H.C. Wainwright Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $26
Express News | ADMA Biologics Inc : Mizuho Raises Target Price to $24 From $20